12 Month Price Forecast For ICCC
Distance to ICCC Price Forecasts
ICCC Price Momentum
🤔 Considering ImmuCell (ICCC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 1:49 PM UTC
ICCC Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for ICCC (ImmuCell).
ICCC is currently trading at $4.64. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICCC Analyst Consensus
ICCC Price Target Range
Latest ICCC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICCC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $14.00 |
ImmuCell Corp (ICCC) Financial Data
ImmuCell Corp has a market capitalization of $43.58M with a P/E ratio of 0.0x. The company generates $23.22M in trailing twelve-month revenue with a -17.4% profit margin.
Revenue growth is +54.9% quarter-over-quarter, while maintaining an operating margin of -25.3% and return on equity of -16.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
ImmuCell Corp (ICCC) Company Overview
About ImmuCell Corp
Develops health products for cattle.
The company generates revenue by developing, manufacturing, and selling animal health products specifically designed for dairy and beef cattle. Its offerings include preventive and treatment products for various cattle health issues, which are distributed through animal health distributors. By addressing critical health challenges in the cattle industry, the company positions itself as a vital player in enhancing livestock productivity.
ImmuCell operates primarily in two segments: Scours and Mastitis, focusing on products that prevent and treat these common issues among cattle. The company was incorporated in 1982 and is based in Portland, Maine, reflecting a long-standing presence in the animal health market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
75
CEO
Mr. Michael F. Brigham
Country
United States
IPO Year
1995
Website
immucell.comImmuCell Corp (ICCC) Latest News & Analysis
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
9 days agoZacks initiates coverage of ImmuCell with a "Neutral" rating, highlighting its market leadership and growth potential, especially with a mastitis treatment nearing FDA approval.
Zacks' "Neutral" rating on ImmuCell highlights cautious sentiment amid potential growth from FDA approval of its mastitis treatment, impacting stock valuation and investor positioning.
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
24 days agoICCC reports strong Q3 sales growth but is challenged by margin issues. The company is pending FDA approval for its Re-Tain product.
Strong Q3 sales growth indicates demand, potentially increasing stock value. Margin challenges could impact profitability, while FDA approval for Re-Tain is crucial for future revenue potential.
ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript
29 days agoImmuCell Corporation (NASDAQ: ICCC) will hold its Q3 2024 earnings conference call on November 14, 2024, at 9:00 AM ET to discuss unaudited financial results.
Upcoming earnings call may reveal financial health and growth prospects of ImmuCell Corporation, impacting stock performance and investor sentiment.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
1 month agoImmuCell Corporation (Nasdaq: ICCC) reported its unaudited financial results for Q3 2024, focusing on products for dairy and beef cattle health and productivity.
ImmuCell's quarterly financial results may indicate growth potential or challenges, impacting stock performance and investor sentiment in the animal health sector.
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
1 month agoA conference call is scheduled for November 14, 2024, at 9:00 AM ET. Investors should mark their calendars for this event.
A scheduled conference call often indicates upcoming financial updates or strategic discussions, which can influence stock prices and investor sentiment.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
2 months agoImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales results for Q3 2024, ending September 30, focusing on products for dairy and beef cattle health.
Preliminary sales results can signal financial performance trends, impacting stock valuation and investor confidence in ImmuCell's growth potential in the animal health sector.
Frequently Asked Questions About ICCC Stock
What is ImmuCell Corp's (ICCC) stock forecast for 2025?
Analyst forecasts for ImmuCell Corp (ICCC) are not currently available. The stock is trading at $4.64.
Is ICCC stock a good investment in 2025?
Analyst ratings for ICCC are not currently available. The stock is currently trading at $4.64. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ICCC stock?
Price predictions from Wall Street analysts for ICCC are not currently available. The stock is trading at $4.64.
What is ImmuCell Corp's business model?
The company generates revenue by developing, manufacturing, and selling animal health products specifically designed for dairy and beef cattle. Its offerings include preventive and treatment products for various cattle health issues, which are distributed through animal health distributors. By addressing critical health challenges in the cattle industry, the company positions itself as a vital player in enhancing livestock productivity.
What is the highest forecasted price for ICCC ImmuCell Corp?
Price targets from Wall Street analysts for ICCC are not currently available. The stock is trading at $4.64.
What is the lowest forecasted price for ICCC ImmuCell Corp?
Price targets from Wall Street analysts for ICCC are not currently available. The stock is trading at $4.64.
What is the overall ICCC consensus from analysts for ImmuCell Corp?
Analyst ratings for ICCC are not currently available. The stock is trading at $4.64.
How accurate are ICCC stock price projections?
Stock price projections, including those for ImmuCell Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
